Nabriva Therapeutics plc announced that Dr. Mark Corrigan and Lisa Dalton have joined the Company’s Board of Directors. In addition, after many years of service Dr. George Talbot has notified the company of his decision not to stand for re-election to the Board of Directors. Dr. Talbot is expected to continue his service on the Board of Directors until the conclusion of his term at the 2021 Annual General Meeting of Shareholders. Dr. Corrigan is a highly successful pharmaceutical executive with 30 years of industry experience, including roles as CEO, Global R&D Lead and serving on the Boards of other biotech companies. Dr. Corrigan currently serves as Chairman of the Board of Exacis Therapeutics, as well as Co-Founder and Board Member of Tremeau Pharmaceuticals Inc. Ms. Dalton is a highly experienced pharmaceutical and biotechnology executive with over 25 years in the industry. Currently Ms. Dalton serves as Chief People Officer at Spark Therapeutics Inc. (Roche Holdings AG). Prior to joining Spark, Ms. Dalton spent 10 years at Shire plc (now Takeda) in various leadership roles within the Human Resources function.